Skip to content

A Clinical Study to Assess Eye Lite Roll-On for Improving Dark Circles and Puffiness Under the Eyes

An Open-Label, Single-Arm, Interventional Clinical Study to Evaluate the Efficacy and Safety of Eye Lite Roll-On for Reduction of Under-Eye Dark Circles and Puffiness Over a Period of 14 Days - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/109562
Enrollment
34
Registered
2026-04-28
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Eye Lite Roll-On: Topical roll-on formulation applied to the under-eye (peri-orbital) area twice daily (morning and evening) for 14 days Control Intervention1: Not Applicable: This is a

Sponsors

SKINOVATE LASER & COSMETIC SURGERY CENTRE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Healthy male and female subjects aged 18 60 years Visible mild to moderate under-eye dark circles and puffiness Good general health with no significant medical conditions Fitzpatrick skin types I IV Willingness to provide written informed consent

Exclusion criteria

Exclusion criteria: Active skin conditions around the eye (eczema, dermatitis, infection) History of hypersensitivity to cosmetic products Use of: Eye creams/treatments within 2 weeks Systemic medication affecting skin within 4 weeks Recent cosmetic procedures (fillers, peels, lasers) in under-eye area Pregnant or breastfeeding women Participation in another clinical study within 30 days Any condition that may interfere with study evaluation

Design outcomes

Primary

MeasureTime frame
To assess the reduction in under-eye dark circles after 14 days of product useTimepoint: To assess the reduction in under-eye dark circles after 14 days of product use

Secondary

MeasureTime frame
To evaluate reduction in under-eye puffiness To assess skin smoothness and hydration (peri-orbital area) To evaluate product safety and tolerability Timepoint: 14 Days

Countries

India

Contacts

Public ContactDr Avinash Bajirao Jadhav

Punawale Multispecialty Hospital

dr.avinashjadhav2@gmail.com07378306651

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026